Riding the Trend or Protecting Profits | Concert Pharmaceuticals Inc. (CNCE) – News Heater
Home  »  Hot Stocks   »  Riding the Trend or Protecting Profits | Concert P...

Riding the Trend or Protecting Profits | Concert Pharmaceuticals Inc. (CNCE)

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) went up by 22.78% from its latest closing price compared to the recent 1-year high of $4.62. The company’s stock price has collected 5.83% of gains in the last five trading sessions.

Is It Worth Investing in Concert Pharmaceuticals Inc. (NASDAQ :CNCE) Right Now?

Plus, the 36-month beta value for CNCE is at 0.40. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Concert Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $13.08, which is $9.63 above the current price. CNCE currently public float of 33.99M and currently shorts hold a 0.40% ratio of that float. Today, the average trading volume of CNCE was 66.65K shares.

CNCE’s Market Performance

CNCE stocks went up by 5.83% for the week, with a monthly jump of 9.52% and a quarterly performance of 5.83%, while its annual performance rate touched -11.31%. The volatility ratio for the week stands at 8.09% while the volatility levels for the past 30 days are set at 6.46% for Concert Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 9.65% for CNCE stocks with a simple moving average of 4.74% for the last 200 days.

Analysts’ Opinion of CNCE

Many brokerage firms have already submitted their reports for CNCE stocks, with Berenberg repeating the rating for CNCE by listing it as a “Buy.” The predicted price for CNCE in the upcoming period, according to Berenberg is $25 based on the research report published on December 16th of the previous year 2020.

Jefferies, on the other hand, stated in their research note that they expect to see CNCE reach a price target of $23. The rating they have provided for CNCE stocks is “Buy” according to the report published on March 30th, 2020.

H.C. Wainwright gave a rating of “Buy” to CNCE, setting the target price at $25 in the report published on October 03rd of the previous year.

CNCE Trading at 6.47% from the 50-Day Moving Average

After a stumble in the market that brought CNCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.32% of loss for the given period.

Volatility was left at 6.46%, however, over the last 30 days, the volatility rate increased by 8.09%, as shares surge +5.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.01% upper at present.

During the last 5 trading sessions, CNCE rose by +5.83%, which changed the moving average for the period of 200-days by -0.29% in comparison to the 20-day moving average, which settled at $3.16. In addition, Concert Pharmaceuticals Inc. saw 9.52% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CNCE starting from Tung Roger D, who sale 13,480 shares at the price of $3.09 back on Feb 15. After this action, Tung Roger D now owns 980,258 shares of Concert Pharmaceuticals Inc., valued at $41,653 using the latest closing price.

Stuart Nancy, the Chief Operating Officer of Concert Pharmaceuticals Inc., sale 6,049 shares at $3.08 during a trade that took place back on Feb 14, which means that Stuart Nancy is holding 284,737 shares at $18,631 based on the most recent closing price.

Stock Fundamentals for CNCE

Current profitability levels for the company are sitting at:

  • -237.92 for the present operating margin
  • +94.28 for the gross margin

The net margin for Concert Pharmaceuticals Inc. stands at -245.72.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.32.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam